News Focus

Genomania Meets the Bottom Line

Science  16 Feb 2001:
Vol. 291, Issue 5507, pp. 1193-1203
DOI: 10.1126/science.291.5507.1193

You are currently viewing the summary.

View Full Text

Summary

Many financial analysts remain wary of the growing genomics industry. Although a record number of self-proclaimed genomics firms went public last year, and a few established firms saw their stock prices temporarily skyrocket in anticipation of the completion of the human genome, longtime observers note that most genomics companies have yet to turn a profit. Even some high-profile players, such as information broker Celera Genomics of Rockville, Maryland, are still struggling to figure out how they will ultimately make money (see sidebar).